Hamostaseologie 2008; 28(S 01): S113
DOI: 10.1055/s-0037-1621604
Original article
Schattauer GmbH

Inzidenz des erworbenen VWS bei 41 Patienten mit myeloproliferativen Erkrankungen

Incidence of acquired von Willebrand disease in 41 patients suffering from myeloproliferative disorders
C. von Auer
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
,
C. Flick
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
,
I. Scharrer
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
04 January 2018 (online)

 

 
  • Literatur

  • 1 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (01) 48-S58.
  • 2 Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Exp Opin Invest Drugs 2000; 9 (02) 347-354.
  • 3 Federici AB, Jacob H. et al. Acquired von Wille-brand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
  • 4 Murugesan G, Aboudola S, Szpurka H. et al. Identification of the JAK2 V617F mutation in chronic myeloproliferaative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006; 125: 625-633.
  • 5 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
  • 6 Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F ea. Am Soc Hematol 2006; 240-245.
  • 7 Budde U. et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1984; 68: 981-985.